Mostrar el registro sencillo del ítem

dc.contributor.authorDu, Chengli
dc.contributor.authorCai, Jin
dc.contributor.authorTang, Jie
dc.contributor.authorChen, Yunhao
dc.contributor.authorDíaz-Peña, Roberto
dc.contributor.authorTomita, Yusuke
dc.contributor.authorJassem, Jacek
dc.contributor.authorZhao, Jiangang
dc.contributor.authorZheng, Difang
dc.contributor.authorTu, Zhengliang
dc.date.accessioned2024-04-09T23:06:00Z
dc.date.available2024-04-09T23:06:00Z
dc.date.issued2024
dc.identifier10.21037/jtd-23-1827
dc.identifier.issn20721439
dc.identifier.urihttps://hdl.handle.net/20.500.12728/10342
dc.description.abstractBackground: Aberrant methylation plays an essential role in early cancer development. In this study, we investigated methylation patterns in lung squamous cell carcinoma (LUSC) and matched non-tumor tissue and plasma samples to evaluate the potential of these patterns in the diagnosis of LUSC. Methods: The study group included 49 patients with stage I-III LUSC. We collected resected tumor tissue, paired peritumoral tissue, distant normal tissue, and corresponding plasma samples. A bespoke lung cancer bisulfite sequencing panel was used to profile the methylation level. Another 48 healthy volunteers provided control plasma samples.Results: Peritumoral and distant normal tissues presented similar methylation signatures, distinct from those in tumor tissue samples. A comparison of methylation profiles led to the identification of 871 tumor-specific differentially methylated blocks, including 847 hypermethylated and 24 hypomethylated blocks (adjusted P value <0.05). All top-ranked blocks were tumor-related. Tissue samples were analyzed for field cancerization to identify progressively aggravating aberrant methylations during tumor initiation and development. The analysis revealed that 221 blocks presented a stepwise increase in methylation levels, while seven blocks presented a stepwise decrease in methylation pattern as the sampling drew nearer to the tumor. The malignant contaminated ratio (MCR) confirmed the presence of distinct methylation patterns between tumor and peritumoral tissue samples. We then constructed a diagnostic panel using a combined diagnostic score of cell-free DNA (cfDNA) that showed high sensitivity and specificity. The healthy controls had a significantly lower combined diagnostic score (cd-score) than LUSC patients. Additionally, based on the methylation profiles, LUSC could be classified into two subgroups, C1 and C2. The methylation profile of the C2 group was not distinct from the healthy controls, which had a significantly lower cd-score than did the C1 group. Conclusions: LUSC-specific methylation patterns could potentially discriminate between peritumoral tissue, distant normal tumor tissue, and tumor tissues. This preliminary study also supported the potential utility of cfDNA methylation analysis in diagnosing LUSC. © 2024 AME Publishing Company. All rights reserved.es_ES
dc.language.isoenes_ES
dc.publisherAME Publishing Companyes_ES
dc.subjectcell-free DNA (cfDNA)es_ES
dc.subjectcombined diagnostic score (cd-score)es_ES
dc.subjectlung squamous cell carcinoma (LUSC)es_ES
dc.subjectMethylation patternses_ES
dc.titleCell-free DNA methylation profile potential in the diagnosis of lung squamous cell carcinomaes_ES
dc.typeArticlees_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem